After closing the Agential Cannabis conference in Bangkok last month, Stephen Murphy, founder and CEO of Prohibition Partners, considers how medicinal cannabis in the Asia-Pacific region is taking shape and what will determine leadership in the region over the next five years.
Australia’s New South Wales has moved to end the automatic penalisation of medicinal cannabis patients caught driving with THC in their system, introducing a registration and threshold-based framework that leaves most of Australia’s one million cannabis patients still without equivalent protection.
Canadian cannabis exports totalled CA$51.6 million in February 2026 across the three main cannabis HS codes tracked in export data, up 8.7% on the same month a year earlier.
The UK and Germany’s medical cannabis markets both more than doubled in size throughout 2025, once again cementing the countries as the engine behind European market growth.
The medical cannabis industries in Australia and New Zealand are continuing to evolve rapidly, with both markets showing signs of maturation, regulatory recalibration, and expanding export ambitions, according to new data.
Australia’s thriving medical cannabis industry has continued its blistering levels of growth, seeing the amount of medical cannabis imported grow nearly tenfold in just three years, according to new official data.
Germany’s Ministry of Health has now published a long-feared draft amendment to its Medical Cannabis Act (MedCanG), threatening a crackdown which will be a major cause for concern for hundreds of cannabis businesses, both in and outside of German borders.
Ahead of the Cannabis Europa 2026, which kicks off next Tuesday (June 24) at the Barbican Centre, we caught up with Eidan Havas, the Founder of one of Australia’s leading medical cannabis product wholesalers, The Entourage Effect.
Medical cannabis clinics are often driven to scale their operations quickly, out of a desire to reach more patients who could benefit from treatment and the need to remain affordable for them. But doing so shouldn’t come at the cost of regulatory compliance.
